行情

IMMP

IMMP

Immutep
NASDAQ

实时行情|Nasdaq Last Sale

2.410
-0.200
-7.66%
盘前: 2.340 -0.07 -2.90% 08:33 03/05 EST
开盘
2.560
昨收
2.610
最高
2.564
最低
2.310
成交量
357
成交额
--
52周最高
7.95
52周最低
0.5300
市值
1.56亿
市盈率(TTM)
-0.5565
分时
5日
1月
3月
1年
5年
Immutep确认昨天的报告共同扩展了TACTI-002研究的B部分
Immutep Expands Part B of TACTI-002 Study Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited ((ASX: IMM, NASDAQ:IMMP) a biotechnology company developing novel immunotherapyImmutep Expands Part B of TACTI-002 Study
Benzinga · 57分钟前
Immutep扩展了TACTI-002合作试验的B部分
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02350087-2A1285197?access_token=83ff96335c2d45a094df02a206a39ff4
Benzinga · 16小时前
面向革兰氏阳性细菌感染的全球药物市场分析2021年:行业规模,CAGR(按地域划分),业务挑战以及到2025年的需求状况增长预测
Feb 04, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Drugs For Gram-Positive Bacterial...
The Express Wire · 02/04 06:52
每日生物技术脉动:索伦托,COVID-19研究数据的免疫突变,T2生物系统在公告前下沉
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26)
Benzinga · 01/27 12:35
每日生物技术脉动:索伦托,COVID-19研究数据的免疫突变,T2生物系统在公告前下沉
Benzinga · 01/27 12:35
Immutep(IMMP)获得Alliance Global Partners的买入评级
SmarterAnalyst · 01/26 12:15
每日生物技术脉搏:Fluidigm基于唾液的COVID测试在欧洲获得批准,中国支持Amarin的Vascepa
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21)
Benzinga · 01/22 12:22
每日生物技术脉搏:Fluidigm基于唾液的COVID测试在欧洲获得批准,中国支持Amarin的Vascepa
Benzinga · 01/22 12:22
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解IMMP最新的财务预测,通过IMMP每股收益,每股净资产,每股现金流等数据分析Immutep近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测IMMP价格均价为6.14,最高价位7.76,最低价为4.848。
EPS
机构持股
总机构数: 18
机构持股: 68.01万
持股比例: 1.05%
总股本: 6,487.25万
类型机构数股数
增持
2
9.60万
建仓
7
6.16万
减持
0
0
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-3.62%
制药与医学研究
-2.13%
高管信息
Non-Executive Chairman
Russell Howard
Chief Executive Officer/Executive Director
Marc Voigt
Non-Executive Vice Chairman
Pete Meyers
Chief Operating Officer/General Counsel/Secretary
Deanne Miller
Chief Scientific Officer
Frederic Triebel
Non-Executive Director
Grant Chamberlain
暂无数据
IMMP 简况
Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.

微牛提供Immutep Ltd(NASDAQ-IMMP)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的IMMP股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IMMP股票基本功能。